Daniel C. Cho
Impact in
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
-
- Renal cell carcinoma treatment
Papers in
- Oncology 30
- Cancer Immunotherapy and Biomarkers 21
- CAR-T cell therapy research 8
-
- Renal cell carcinoma treatment 24
- Co-authors
- Michael B. Atkins (17 shared papers)David F. McDermott (20 shared papers)Chiara Battelli (1 shared paper)James W. Mier (9 shared papers)Toni K. Choueiri (11 shared papers)Igor Puzanov (9 shared papers)David J. Panka (4 shared papers)Sabina Signoretti (2 shared papers)
- Journals
- Journal of Clinical Oncology (29 papers)Clinical Cancer Research (3 papers)Journal for ImmunoTherapy of Cancer (3 papers)Molecular Cancer Therapeutics (2 papers)Cancer (2 papers)
- Partner nations
- United StatesUnited KingdomItaly
In The Last Decade
Daniel C. Cho
63 papers receiving 1.8k citations
Daniel C. Cho's Hit Papers
Peers
Comparison fields: 5 of 73
- Oncology 774
- Pulmonary and Respiratory Medicine 738
- Cancer Research 318
- Immunology 325
- Molecular Biology 774
Countries citing papers authored by Daniel C. Cho
This map shows the geographic impact of Daniel C. Cho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel C. Cho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel C. Cho more than expected).
Fields of papers citing papers by Daniel C. Cho
This network shows the impact of papers produced by Daniel C. Cho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel C. Cho. The network helps show where Daniel C. Cho may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel C. Cho, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 64 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial Hit paper breakdown → | 2018 | 279 |
| 2 | 2010 | 164 | |
| 3 | 2019 | 118 | |
| 4 | 2011 | 93 | |
| 5 | 2021 | 93 | |
| 6 | 2013 | 86 | |
| 7 | 2012 | 80 | |
| 8 | 2010 | 76 | |
| 9 | 2022 | 51 | |
| 10 | 2007 | 46 | |
| 11 | 2018 | 41 | |
| 12 | 2009 | 38 | |
| 13 | 2012 | 37 | |
| 14 | 2017 | 33 | |
| 15 | 2021 | 32 | |
| 16 | 2018 | 29 | |
| 17 | 2020 | 28 | |
| 18 | 2019 | 27 | |
| 19 | 2012 | 26 | |
| 20 | 2016 | 24 |
About Daniel C. Cho
Daniel C. Cho is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research and Immunology, having authored 64 papers that have together received 1.8k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (24 papers), Cancer Immunotherapy and Biomarkers (21 papers), Cancer Genomics and Diagnostics (8 papers), CAR-T cell therapy research (8 papers), PI3K/AKT/mTOR signaling in cancer (7 papers), Renal and related cancers (5 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Bladder and Urothelial Cancer Treatments (4 papers). The work is most often cited by research in Oncology (774 citations), Pulmonary and Respiratory Medicine (738 citations), Cancer Research (318 citations), Immunology (325 citations) and Molecular Biology (774 citations). Daniel C. Cho has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Michael B. Atkins, David F. McDermott, Chiara Battelli, James W. Mier, Toni K. Choueiri, Igor Puzanov, David J. Panka, Sabina Signoretti, Mayer Fishman and Ulka N. Vaishampayan. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Journal for ImmunoTherapy of Cancer, Molecular Cancer Therapeutics and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.